作者
M Shahar Yar, Kashif Haider, Vivek Gohel, Nasir Ali Siddiqui, Ahmed Kamal
发表日期
2020/7/2
来源
Expert opinion on drug discovery
卷号
15
期号
7
页码范围
823-832
出版商
Taylor & Francis
简介
Introduction
A novel anticancer therapy is the need of the hour due to growing incidences of resistance to first line cancer chemotherapy. Synthetic lethality (SL) is one of the new age treatment methods being explored for combating the resistance to anticancer agents. In this method, cell mutations are exploited for the development of new therapeutic agents, where, if there is loss of function of one gene, the cell mutations can still be fixed by alternative machinery but if two genes involved in DNA repair undergo loss of function, it causes lethality to the cell.
Areas covered
The authors condense findings of SL-based novel anticancer regimen. The review emphasizes some of the SL based clinical and preclinical studies of novel targets and therapy.
Expert opinion
SL conceptualizes a resolution against treatment resistance to anticancer regimen by recognition of therapeutic vulnerabilities in particular cancer cells. A …
引用总数
2020202120222023202424824
学术搜索中的文章
MS Yar, K Haider, V Gohel, NA Siddiqui, A Kamal - Expert Opinion on Drug Discovery, 2020